Atelerix, a biotech innovator specializing in cell preservation through hydrogel encapsulation technology, has entered into a strategic partnership with Cherry Biotech, a French company known for its advancements in organ-on-chip and organoid technologies. This collaboration aims to integrate Atelerix’s hydrogel technology with Cherry Biotech’s sophisticated 3D organoid models, facilitating the global extended-duration shipment of temperature-sensitive materials.
The partnership is set to enhance the reliability and consistency of transporting these materials without the complexities of cold-chain logistics, thereby enabling broader access to high-quality, human-relevant preclinical data. An initial 12-month trial will validate the strategic and technical alignment of both companies, laying the foundation for a scalable, long-term commercial relationship.
Cherry Biotech’s in vitro offerings leverage AI analysis, high-resolution live imaging, and controlled organoid culture to better predict drug efficacy and safety. The collaboration will also validate the stable shipment of Cherry Biotech’s organoidPlate, which contains ready-to-use organoids for various tissue types, now available for global distribution. This partnership is viewed as a significant step for Atelerix in expanding its market reach and visibility, according to CEO Alastair Carrington, who emphasizes the potential of ambient logistics in advancing drug testing methodologies.
Cherry Biotech’s CBO, Pierre Gaudriault, highlights that Atelerix’s hydrogel technology enhances cell viability during transport, eliminating cold-chain constraints and reducing environmental impact. This innovation promises to deliver unprecedented convenience and reliability to researchers in both pharmaceutical and academic settings, marking a pivotal advancement in the logistics of organoid model distribution.
Get started today with Solo access →
